Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first half of 2025, continuing a trend of decreasing performance that began last year [2][3] Financial Performance - In the first half of 2025, the company achieved revenue of approximately 413 million yuan, a year-on-year decrease of 21.08% [2] - The net profit attributable to shareholders was a loss of approximately 92.39 million yuan, a year-on-year decrease of 451.68% [2] - For the full year of 2024, the company reported revenue of 1.132 billion yuan, down 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [4][5] Core Business Segment - The pharmaceutical segment, which is the core business, faced significant revenue pressure, generating sales of 356 million yuan in the first half of 2025, a decline of 24.25% year-on-year, accounting for 86.08% of total revenue [3][4] - Revenue from infusion products was 132 million yuan, down 12.14% year-on-year [4] - Non-infusion products saw growth in sales due to successful bidding in centralized procurement, but the revenue from small-volume injectables dropped by 37.91% due to a 56.85% price reduction on a key product [4] New Business Segments - The animal health and wellness sectors, which the company has been focusing on, have not yet become significant contributors to revenue and are still in the investment phase [6] - Revenue from functional foods, cosmetics, veterinary drugs, and feed additives accounted for only 7.21% of total revenue in 2024 [7] Subsidiary Performance - The company’s two wholly-owned subsidiaries, Lanxi Pharmaceutical and Lingbao Sanlian, contributed to the overall losses [8] - Lanxi Pharmaceutical reduced sales to the parent company due to previous stockpiling of raw materials, leading to a significant drop in revenue [8] - Lingbao Sanlian, in its initial phase, reported negative profit margins and increased depreciation costs after reaching operational status [8]